Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Myeloma-associated polyneuropathy responding to lenalidomide.

Layzer R, Wolf J.

Neurology. 2009 Sep 8;73(10):812-3. doi: 10.1212/WNL.0b013e3181b6bb22. No abstract available.

PMID:
19738177
2.

Lenalidomide: new drug. Myeloma: many questions remain unanswered.

[No authors listed]

Prescrire Int. 2008 Dec;17(98):230-2.

PMID:
19422142
3.

[Lenalidomide. Treatment of multiple myeloma].

Musch A.

Med Monatsschr Pharm. 2008 Jan;31(1):4-8; quiz 9-10. Review. German. No abstract available. Erratum in: Med Monatsschr Pharm. 2008 Mar;31(3):106.

PMID:
18522014
4.

Concurrent B-cell chronic lymphocytic leukemia and multiple myeloma treated successfully with lenalidomide.

Srinivasan S, Schiffer CA.

Leuk Res. 2009 Apr;33(4):561-4. doi: 10.1016/j.leukres.2008.06.024. Epub 2008 Aug 3.

PMID:
18676017
5.

A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings.

Stadtmauer EA, Lonial S, Vesole DH, Abonour R, Alsina M, Badros A, Comenzo R, Durie B, Giralt S, Hussein M, Jakubowiak A, Mehta J, Niesvizky R, Orlowski R, Siegel D, Singhal S, Vescio R, Wang M, Zangari M, Munshi NC.

Clin Adv Hematol Oncol. 2007 Oct;5(10 Suppl 15):7-19, quiz 21-2. No abstract available.

PMID:
18000495
6.

A case of severe aplastic anemia secondary to treatment with lenalidomide for multiple myeloma.

Dasanu CA, Alexandrescu DT.

Eur J Haematol. 2009 Mar;82(3):231-4. doi: 10.1111/j.1600-0609.2008.01176.x. Epub 2008 Nov 6.

PMID:
19018868
7.

Thalidomide and lenalidomide: Mechanism-based potential drug combinations.

Vallet S, Palumbo A, Raje N, Boccadoro M, Anderson KC.

Leuk Lymphoma. 2008 Jul;49(7):1238-45. doi: 10.1080/10428190802005191. Review.

PMID:
18452080
8.

[Lenalidomid (Revlimid) in the treatment of multiple myeloma--first experience in the Czech Republic].

Novotová E, Neuwirtová R, Jonásová A, Straub J, Spicka I.

Cas Lek Cesk. 2008;147(12):623-6. Czech.

PMID:
19235487
9.

Infection complications in an unselected cohort of patients with multiple myeloma treated with lenalidomide combinations.

Caravita T, Offidani M, Siniscalchi A, Gentili S, Caraffa P, Perrotti A, de Fabritiis P, Leoni P.

Eur J Haematol. 2012 Sep;89(3):276-7. doi: 10.1111/j.1600-0609.2012.01814.x. Epub 2012 Jul 28. No abstract available.

PMID:
22672700
10.

Lenalidomide, a thalidomide derivative, shows promise in various applications.

Oestreicher P.

ONS Connect. 2007 Aug;22(8):22-3. No abstract available.

PMID:
17824579
11.

Concurrent radiation therapy and lenalidomide in myeloma patient.

Marchand V, Decaudin D, Servois V, Kirova YM.

Radiother Oncol. 2008 Apr;87(1):152-3. Epub 2008 Feb 20. No abstract available.

PMID:
18077032
12.

Thalidomide and lenalidomide: overview of the French pharmacovigilance database.

[No authors listed]

Prescrire Int. 2012 Mar;21(125):72.

PMID:
22428194
13.

Azotemia associated with use of lenalidomide in plasma cell dyscrasias.

Batts ED, Sanchorawala V, Hegerfeldt Y, Lazarus HM.

Leuk Lymphoma. 2008 Jun;49(6):1108-15. doi: 10.1080/10428190802023707.

PMID:
18452093
14.

Neutrophilic dermatosis complicating lenalidomide therapy.

Thieu KP, Rosenbach M, Xu X, Kist JM.

J Am Acad Dermatol. 2009 Oct;61(4):709-10. doi: 10.1016/j.jaad.2008.12.011. Epub 2009 Jul 3.

PMID:
19577327
15.

How to prevent deep vein thrombosis in myeloma patients receiving thalidomide or lenalidomide.

Kastritis E, Dimopoulos M.

Leuk Lymphoma. 2007 Dec;48(12):2295-7. No abstract available.

PMID:
18066998
16.

Potential new risks of lenalidomide.

Gertz MA, Buadi FK.

Leuk Lymphoma. 2014 Sep;55(9):1962-3. doi: 10.3109/10428194.2013.862243. Epub 2014 Jan 28. No abstract available.

PMID:
24304420
17.

[Lenalidomide in the treatment of multiple myeloma].

Machálková K, Maisnar V.

Klin Onkol. 2009;22(3):117-20. Czech.

PMID:
19708546
18.

Successful desensitization in a patient with lenalidomide hypersensitivity.

Phillips J, Kujawa J, Davis-Lorton M, Hindenburg A.

Am J Hematol. 2007 Nov;82(11):1030. No abstract available.

19.

Polyclonal immune activation and marrow plasmacytosis in multiple myeloma patients receiving long-term lenalidomide therapy: incidence and prognostic significance.

Zamarin D, Devlin SM, Arcila ME, Landau H, Lesokhin A, Lendvai N, Chung DJ, Chimento D, Weltz J, Babu D, Giralt S, Hassoun H.

Leukemia. 2013 Dec;27(12):2422-4. doi: 10.1038/leu.2013.126. Epub 2013 Apr 23. No abstract available.

PMID:
23608883
20.

Current therapy of myeloma induced renal failure.

Gertz MA.

Leuk Lymphoma. 2008 May;49(5):833-4. doi: 10.1080/10428190801972482. Review. No abstract available.

PMID:
18452070

Supplemental Content

Support Center